The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.

This self-reported registry data suggest tixa/cil had a very limited role preventing breakthrough SARS-CoV-2 infection in patients with hematologic malignancies during 1 April 2022 to 31 July 2022, when Omicron variant BA.5 was prevalent. One thousand one hundred and ninety-nine patients received tixa/cil, of whom 99% reported to receive a cumulative first dose of 300/300 mg (361 patients received two separate administrations of 150/150 mg dose as a result of the FDA dose revision from 150/150 mg to 300/300 mg). Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Dear Editor, Patients with hematological malignancies who are infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are at an elevated risk for morbidity and mortality due to their age, immunosuppressive therapy, and underlying immunodeficiency [[1], [3]]. [Extracted from the article]